Why take this course?
A nitrosamine risk assessment is often straightforward when the process, materials, suppliers, and product remain unchanged. The truly difficult decisions begin during lifecycle management when something changes. A new supplier is introduced. A reagent is replaced. A manufacturing site is transferred. A formulation is modified. An unexpected analytical result is reported. Teams must determine whether the existing risk assessment remains scientifically defensible or whether a formal reassessment, confirmatory testing, or additional control strategies are required.
This technical webinar focuses entirely on the critical decisions that follow post-approval change. Participants will learn how experienced pharmaceutical organizations evaluate reassessment triggers, determine the significance of supplier, process, formulation, and manufacturing modifications, and decide when physical testing is strictly warranted versus when a scientific rationale suffices. The session will deeply examine the application of ICH M7 purge assessments, the classification of Nitrosamine Drug Substance Related Impurities (NDSRIs) using CPCA principles, the justification of testing strategies, and the development of agile control approaches that remain fully compliant as products, processes, and international regulatory expectations continue to evolve.
Key Areas Covered
Complete Course Agenda
G. Sundar
G. Sundar is a quality practitioner with vast 35 years’ experience in the field of Quality Assurance, Quality Control, Bioequivalence and Pharmaceutical Regulations. His quality management experience covers the implementation of Quality tools in bulk drugs, formulation companies and CRO. He is an expert in Total Quality Systems as per GLP, GDP and as per EMEA, USFDA, MHRA and MCC, TGA, ANVISA, Japan guidelines. He has conducted more than 200 GMP/GLP audits including Q10 & Q11 implementation, 50 Formulation Contract Manufacturing Units (all types of formulations), 10 Contract Research and Analytical laboratories, 10 Clinical research CROs. He has also conducted 1000 plus trainings Asia, US, EU, Middle East and South-East Asia. Mr. Sundar Ganesan is the Director and Senior Consultant at PharmQA Compliance Services.
Commonly Asked Questions About This Subject
How much evidence is enough to justify a root cause conclusion during a GMP investigation?
A root cause conclusion should be supported by evidence that directly links the identified cause to the observed event. Inspection concerns frequently arise when investigations move from suspicion to conclusion without demonstrating that connection. Statements such as "operator error," "lack of attention," or "procedure not followed" often raise additional questions rather than resolving them.
Reviewers typically look for objective support such as records, interviews, historical trends, process data, equipment performance, environmental conditions, or documented observations that point toward the same conclusion. A root cause becomes difficult to defend when equally plausible explanations were not evaluated or eliminated.
Rework commonly occurs when teams stop investigating after finding the first reasonable explanation. Experienced investigators continue until they can explain both how the failure occurred and why existing controls did not prevent it. The strongest investigations leave little ambiguity about why the selected root cause was chosen over competing possibilities and what evidence supports that decision.
Why do repeat deviations continue to occur even after CAPAs have been completed and closed?
An operational failure point appears when CAPA activities focus on correcting the immediate event while leaving the conditions that enabled it untouched. The deviation may disappear temporarily, yet the underlying system remains unchanged.
A review of recurring events often reveals that training was repeated, procedures were revised, or reminders were issued. Those actions may address symptoms without addressing workload pressures, process complexity, unclear responsibilities, equipment limitations, conflicting procedures, weak oversight, or ineffective management controls.
Inspection friction develops when the same event reappears under slightly different circumstances and prior CAPA records show closure without meaningful system improvement. Investigators frequently discover that effectiveness checks only confirmed short-term compliance rather than sustained performance.
Evidence that carries weight includes measurable process improvement, reduction in recurrence rates, control enhancements, revised workflows, resource adjustments, and objective performance monitoring. Sustainable CAPA outcomes are usually associated with changes to the system rather than changes to individual behavior alone.
When is it appropriate to close an investigation without identifying a definitive root cause?
A definitive root cause is not always obtainable, particularly when evidence has been lost, the event cannot be reproduced, or multiple contributing factors remain equally plausible. What becomes difficult to defend is closing the investigation with uncertainty while treating the issue as fully resolved.
Experienced reviewers generally accept that some investigations end with a probable cause rather than a confirmed root cause. Their focus shifts to whether the investigation was thorough, whether alternative explanations were considered, and whether risk was managed appropriately despite the remaining uncertainty.
Documentation often weakens when teams simply state that the root cause could not be determined. Stronger records explain what evidence was reviewed, what investigative paths were pursued, why additional conclusions could not be supported, and how residual risk will be controlled.
Inspection discussions tend to be far more productive when uncertainty is acknowledged and managed than when unsupported certainty is documented simply to satisfy a procedural expectation.
What distinguishes a strong management review of investigations from a routine approval signature?
A governance concern emerges when management approval becomes a documentation checkpoint rather than an evaluation of investigation quality. Inspectors frequently recognize the difference within minutes of reviewing investigation files.
Strong management oversight focuses on the logic behind conclusions, adequacy of evidence, quality of impact assessments, recurring trends, implementation barriers, and the long-term effectiveness of proposed actions. Questions are raised, assumptions are challenged, and gaps are addressed before closure.
Routine approvals often leave obvious weaknesses untouched. Investigations may contain broad conclusions, incomplete impact evaluations, weak effectiveness measures, or corrective actions that cannot reasonably prevent recurrence. Yet the file carries multiple approval signatures.
Records that demonstrate meaningful management involvement often contain documented comments, requests for additional analysis, escalations, trend reviews, resource decisions, and evidence that leadership evaluated business and quality implications. Those records show active ownership of the process rather than administrative participation.
Your TalkFDA Webinar Experience
1. Confirmation
3. Join the Live Training
4. Watch Again Anytime
Testimonials
Ready to Strengthen Your Team? Let’s Build Your Training Plan.
Your team deserves the clarity.
Your organization deserves the confidence.


